The Analytical Pharmacology Core Facility (APCF) encourages and facilitates collaborative research among COHCCC basic scientists and clinicians by providing a wide range of analytical and consultative services. APCF assists with the design and conduct of pharmacokinetic studies for clinical and preclinical investigations. Primary services provided are: 1) quantitative assay development and sample analysis (LCMS/ MS, GC/MS, AAS, and HPLC) of drugs, biomarkers, and related compounds, and 2) study design and expert analysis of pharmacokinetic and metabolite data. APCF is located in the Shapiro Building and all of the major analytical equipment is consolidated into a contiguous suite of rooms. The most heavily utilized major equipment within the core are the 3 LC-MS/MS instruments, including a Micromass Quattro Ultima triple quad, a Waters Quattro Premier XE triple quad, and an AB Sciex QTRAP 5500. Each of these instruments includes different HPLC components with unique features that provide greater flexibility, and each of the systems provides state-of-the-art selectivity and sensitivity for analytes in complex biological matrices. Instrument control and data acquisition for the Micromass and Waters systems are coordinated through separate MassLynx-NT Workstations running MassLynx and QuanLynx software. MetaboLynx software is also available for the Quattro Premier XE to aid in metabolite identification. Instrument control and data analysis for the QTRAP 5500 is performed on a dedicated workstation running Analyst software. Additional core equipment includes: a Shimadzu Model QP-5000 El gas chromatograph/mass spectrometer, interfaced directly to a dedicated PC running CLASS-5000 software;a Perkin Elmer AAnalyst 300 AAS with an HGA 800 graphite furnace for determination of metals and metal containing compounds;and three complete HPLC systems consisting of six solvent delivery modules (4 Shimadzu LC-IOA's, 2 Shimadzu LClOAD's). HPLC detection capabilities cover a wide range of currently available methods, including UV/Vis (Shimadzu SPD-10AV), fluorescence (Shimadzu RF-10A), electrochemical (ESA models 51 OOA and 5200A), and photodiode array (Waters Acquity PDA) detection systems. Between July 1, 2010 and June 30, 2011, a total of 13 analytical methods were developed or re-initiated, 2657 samples analyzed, and 907 clinical samples processed during the reporting period.

Public Health Relevance

The overall goal of the Analytical Pharmacology Core Facility is to assist with the design and conduct of pharmacology studies and encourage collaborative research between basic scientists and clinicians utilizing state-of-the-art equipment and analytical software. This goal promotes the Cancer Center's mission of developing innovative new disease-fighting strategies in the battle against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-30
Application #
8450535
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2017-11-30
Budget Start
2013-04-25
Budget End
2013-11-30
Support Year
30
Fiscal Year
2013
Total Cost
$73,439
Indirect Cost
$29,726
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Salhotra, A; Tsai, N; Thomas, S H et al. (2015) Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50:139-41
Ali, H; Palmer, J; Eroglu, Z et al. (2015) Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplant 50:307-9
Behrendt, Carolyn E; Hurria, Arti; Tumyan, Lusine et al. (2014) Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. J Natl Compr Canc Netw 12:1579-85
Yang, Lixin; Perez, Aldwin Apollo; Fujie, Sayuri et al. (2014) Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14:124
Gillis, Peter A; Hernandez-Alvarado, Nelmary; Gnanandarajah, Josephine S et al. (2014) Development of a novel, guinea pig-specific IFN-? ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 32:3963-70
Chen, Shiuan; Zhou, Dujin; Hsin, Li-Yu et al. (2014) AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci 139:198-209
Bhatia, Smita; Landier, Wendy; Hageman, Lindsey et al. (2014) 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 124:2345-53
Sun, Virginia; Grant, Marcia; McMullen, Carmit K et al. (2014) From diagnosis through survivorship: health-care experiences of colorectal cancer survivors with ostomies. Support Care Cancer 22:1563-70

Showing the most recent 10 out of 912 publications